Reported Saturday, Johnson & Johnson Reports 57% Of Psoriatic Arthritis Patients With Qualifying Skin Involvement On ICOTYDE Achieved Clear Or Almost Clear Skin Versus 14% On Placebo, Alongside 58% ACR20 Response At Week 16

By Benzinga Newsdesk

li>Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16/li>li>ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily pill/li>

Share this article

Keep reading.

TUTORIALS

Reported Saturday, Johnson & Johnson Reports 57% Of Psoriatic Arthritis Patients With Qualifying Skin Involvement On ICOTYDE Achieved Clear Or Almost Clear Skin Versus 14% On Placebo, Alongside 58% ACR20 Response At Week 16

TUTORIALS

Reported Saturday, Johnson & Johnson Says Patient Insights From Phase 2 DAHLIAS Study Helped Inform Phase 3 Nipocalimab Design, With 73.5% Of Interviewed Patients Satisfied Or Very Satisfied With Treatment In Sjögren’s Disease

TUTORIALS

'EU Sues IBM and Partners Over Troubled Border System' - FT

Trade what
you just read.

Apply the analysis on a live or demo account, same execution, no risk on demo.

Your seat at the market is ready.

Open your account in minutes, transparent pricing, fast withdrawals and support that answers.

Try a free demo

Reported Saturday, Johnson & Johnson Reports 57% Of Psoriatic Arthritis Patients With Qualifying Skin Involvement On ICOTYDE Achieved Clear Or Almost Clear Skin Versus 14% On Placebo, Alongside 58% ACR20 Response At Week 16

Trade whatyou just read.

Your seat at the market is ready.

Trade what
you just read.